Clinical efficacy and mechanism of mesenchymal stromal cells in treatment of COVID-19

被引：0
作者：
Kun Lu
Shi-tao Geng
Shikai Tang
Hua Yang
Wei Xiong
Fang Xu
Qijun Yuan
Xian Xiao
Renqiang Huang
Haihui Liang
Zhipeng Chen
Chuanyun Qian
Yang Li
Songqing Wang
机构：
[1] First Naval Hospital of Southern Theater Command,Department of Neurosurgery
[2] First Naval Hospital of Southern Theater Command,Department of Emergency
[3] First Affiliated Hospital of Kunming Medical University,Department of Emergency
来源：
Stem Cell Research & Therapy | / 13卷
关键词：
Coronavirus disease 2019; Mesenchymal stromal cells; Clinical efficacy; Immunomodulation; Tissue repair;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Coronavirus disease 2019 (COVID-19) is a highly infectious epidemic disease that has seriously affected human health worldwide. To date, however, there is still no definitive drug for the treatment of COVID-19. Cell-based therapies could represent a new breakthrough. Over the past several decades, mesenchymal stromal cells (MSCs) have proven to be ideal candidates for the treatment of many viral infectious diseases due to their immunomodulatory and tissue repair or regeneration promoting properties, and several relevant clinical trials for the treatment of COVID-19 have been registered internationally. Herein, we systematically summarize the clinical efficacy of MSCs in the treatment of COVID-19 based on published results, including mortality, time to symptom improvement, computed tomography (CT) imaging, cytokines, and safety, while elaborating on the possible mechanisms underpinning the effects of MSCs, to provide a reference for subsequent studies.
引用
收藏
相关论文
共 317 条
[1]  
Li H(2020)SARS-CoV-2 and viral sepsis: observations and hypotheses Lancet 395 1517-1520
[2]  
Liu L(2020)Mesenchymal stem cells and management of COVID-19 pneumonia Med Drug Discov 5 100019-847
[3]  
Zhang D(2020)Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia J Thromb Haemost 18 844-1034
[4]  
Xu J(2020)COVID-19: consider cytokine storm syndromes and immunosuppression Lancet 395 1033-412
[5]  
Dai H(2020)Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment BMB Rep 53 400-329
[6]  
Tang N(2014)Therapeutic potential and mechanisms of action of mesenchymal stromal cells for Acute Respiratory Distress Syndrome Curr Stem Cell Res Ther 9 319-324
[7]  
Metcalfe SM(2017)Concise review: mesenchymal stem (stromal) cells: biology and preclinical evidence for therapeutic potential for organ dysfunction following trauma or sepsis Stem Cells 35 316-102
[8]  
Tang N(2020)Current understanding of the therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome Cell Biol Toxicol 36 83-273
[9]  
Li D(2017)Fifty years of research in ARDS. Cell-based therapy for acute respiratory distress syndrome. Biology and potential therapeutic value Am J Respir Crit Care Med 196 266-4621
[10]  
Wang X(2020)Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes Med Hypotheses 144 109865-33
12345678910